Expression of the MOZ-TIF2 oncoprotein in mice represses senescence.
Authors
Largeot, AnnePerez-Campo, Flor-Maria
Marinopoulou, Elli
Lie-A-Ling, Michael
Kouskoff, Valerie
Lacaud, Georges
Affiliation
Cancer Research UK Stem Cell Biology Group, CR-UK Manchester Institute, The University of Manchester, Wilmslow road, ManchesterIssue Date
2016-02-05
Metadata
Show full item recordAbstract
The MOZ-TIF2 translocation, which fuses monocytic leukemia zinc finger protein (MOZ) histone acetyltransferase (HAT) with the nuclear co-activator TIF2, is associated the development of acute myeloid leukemia. We recently found that in the absence of MOZ HAT activity, p16(INK4a) transcriptional levels are significantly increased, triggering an early entrance into replicative senescence. Because oncogenic fusion proteins must bypass cellular safeguard mechanisms, such as senescence and apoptosis, to induce leukemia, we hypothesized that this repressive activity of MOZ over p16(INK4a) transcription could be preserved, or even reinforced, in MOZ leukemogenic fusion proteins, such as MOZ-TIF2. We describe here that, indeed, MOZ-TIF2 silences expression of the CDKN2A locus (p16(INK4a) and p19(ARF)), inhibits the triggering of senescence, and enhances proliferation, providing conditions favorable to the development of leukemia. Furthermore, we describe that abolishing the MOZ HAT activity of the fusion protein leads to a significant increase in expression of the CDKN2A locus and the number of hematopoietic progenitors undergoing senescence. Finally, we report that inhibition of senescence by MOZ-TIF2 is associated with increased apoptosis, suggesting a role for the fusion protein in p53 apoptosis-versus-senescence balance. Our results underscore the importance of the HAT activity of MOZ, preserved in the fusion protein, for repression of CDKN2A locus transcription and the subsequent block of senescence, a necessary step for the survival of leukemic cells.Citation
Expression of the MOZ-TIF2 oncoprotein in mice represses senescence. 2016: Exp. HematolJournal
Experimental HematologyDOI
10.1016/j.exphem.2015.12.006PubMed ID
26854485Type
ArticleLanguage
enISSN
1873-2399ae974a485f413a2113503eed53cd6c53
10.1016/j.exphem.2015.12.006
Scopus Count
Collections
Related articles
- MOZ-mediated repression of p16(INK) (4) (a) is critical for the self-renewal of neural and hematopoietic stem cells.
- Authors: Perez-Campo FM, Costa G, Lie-A-Ling M, Stifani S, Kouskoff V, Lacaud G
- Issue date: 2014 Jun
- MOZ-TIF2 repression of nuclear receptor-mediated transcription requires multiple domains in MOZ and in the CID domain of TIF2.
- Authors: Yin H, Glass J, Blanchard KL
- Issue date: 2007 Aug 13
- A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes.
- Authors: Smolko AE, Sullivan DW, Olsen SN, Kang H, Whedon SD, Baell JB, Cole PA, Armstrong SA, Kuroda MI
- Issue date: 2024 Jun 25
- Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion.
- Authors: Shima H, Yamagata K, Aikawa Y, Shino M, Koseki H, Shimada H, Kitabayashi I
- Issue date: 2014 Jan
- MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway.
- Authors: Sheikh BN, Phipson B, El-Saafin F, Vanyai HK, Downer NL, Bird MJ, Kueh AJ, May RE, Smyth GK, Voss AK, Thomas T
- Issue date: 2015 Nov 19